Isabella Stettler None;
Francesco Romano None;
Katherine Overbey None;
Cade Bennett None;
Xinyi Ding None;
Itika Garg None;
Filippos Vingopoulos None;
Peyman Razavi None;
Matthew Finn None;
Ioanna Ploumi None;
Mauricio Garcia None;
Sandra Alhoyek None;
Nimesh Patel Alimera Sciences, Alcon, Allergan, Genentech, Eyepoint, Lifesciences Guidepoint, and GLG, Code C (Consultant/Contractor), Financial support from the Retina Innovation Fund, Massachusetts Eye and Ear, Boston, MA, Code F (Financial Support);
Demetrios Vavvas Olix Pharma, Valitor, TwentyTwenty, Sumitomo/Sunovion, Cambridge Polymer Group, Code C (Consultant/Contractor), National Eye Institute, NIH, Research to Prevent Blindness, Loefflers Family Foundation, Yeatts Family Foundation, and Alcon Research Institute, Code F (Financial Support), Drusolv Therapeutics, Code O (Owner), MASS EYE and EAR, Code P (Patent);
Joan Miller Sunovion, Genentech/ Roche, KalVista Pharmaceuticals, ONL Therapeutics, Heidelberg Engineering, Code C (Consultant/Contractor), Lowy Medical Research Institute, National Eye Institute, Heidelberg Engineering, Code F (Financial Support), Ciendias Bio, Code I (Personal Financial Interest), Drusolv Therapeutics, ONL Therapeutics, Valeant Pharmaceuticals/Mass. Eye and Ear, Code P (Patent), Aptinyx, Inc., Sunovion, KalVista Pharmaceuticals, ONL Therapeutics, Valeant Pharmaceuticals/Mass. Eye and Ear, Code R (Recipient), Aptinyx, Inc., ONL Therapeutics, Code S (non-remunerative);
John Miller Alcon, Allergan, Carl Zeiss, Sunovion, Genentech and Topcon, Code C (Consultant/Contractor)